Abstract
CMV reactivation is rare in hematological as well as solid organ malignancies in non-allogeneic stem cell transplant settings. An increasing number of patients undergoing active treatment or follow-up and diagnosed with CMV reactivation in recent years prompted us to investigate the risk factors and outcomes of CMV reactivation or disease. This was a hospital-based retrospective study that included 174 cancer patients suspected of CMV reactivation. Among them, forty-one tested positive for CMV viremia. The risk factors for CMV reactivation included the use of steroids in 78% of patients, active cancer in 43.9%, use of a monoclonal antibody rituximab in 31.7%, a history of radiation in 26.8%, and autologous stem cell transplant in 12% of patients. The median age was 36 years, and the most common clinical feature was fever (58.5%; n = 24), followed by GI symptoms (12.1%; n = 5), respiratory symptoms (14.6%; n = 6), cytopenia (7.3%; n = 3), and visual/neurological symptoms (4.8%; n = 2). The mean CMV viral load was 37,332 copies/ml (range: 75.00–633,000.00 copies/ml). Nineteen patients received CMV treatment with an average treatment duration of 81.5 days. The median overall survival was 2 months, with 12.0% of patients alive at 5 years. CMV reactivation is associated with significant morbidity and mortality. We recommend vigilant monitoring of CMV-related symptoms, with a low threshold for testing and treatment, for patients with multiple risk factors for CMV reactivation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Al-Omari A, Aljamaan F, Alhazzani W, Salih S, Arabi Y. Cytomegalovirus infection in immunocompetent critically ill adults: literature review. Ann Intensive Care. 2016;6:110. https://doi.org/10.1186/s13613-016-0207-8.
Alonso-Álvarez S, Colado E, Moro-García MA, Alonso-Arias R. Cytomegalovirus in haematological tumours. Front Immunol. 2021;12:703256. https://doi.org/10.3389/fimmu.2021.703256.
Anastasopoulou A, Samarkos S, Diamantopoulos P, Vourlakou C, Ziogas DC, et al. Cytomegalovirus infections in patients treated with immune checkpoint inhibitors for solid malignancies. Open Forum Infect Dis. 2023;10:ofad164. https://doi.org/10.1093/ofid/ofad164.
Boeckh M, Geballe A. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest. 2011;121:1673–80. https://doi.org/10.1172/JCI45449.
Le Clech L, Ianotto J, Quintin-Roue I, Tempescul A. Severe CMV complication following maintenance therapy with rituximab. BMJ Case Rep. 2013. https://doi.org/10.1136/bcr-2012-006672.
Einsele H, Ljungman P, Boeckh M. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood. 2020;135:1619–29. https://doi.org/10.1182/blood.2019000956.
Forte E, Zhang Z, Thorp EB, Hummel M. Cytomegalovirus latency and reactivation: an intricate interplay with the host immune response. Front Cell Infect Microbiol. 2020;10:130. https://doi.org/10.3389/fcimb.2020.00130.
Goerig NL, Frey B, Korn K, et al. Frequent occurrence of therapeutically reversible CMV-associated encephalopathy during radiotherapy of the brain. Neuro Oncol. 2016;18:1664–72. https://doi.org/10.1093/neuonc/now120.
Goerig N, Semrau S, Frey B, et al. Clinically significant CMV (re)activation during or after radiotherapy/chemotherapy of the brain: correlation with neurological deterioration and improvement upon antiviral treatment. Strahlenther Onkol. 2016;192:489–97. https://doi.org/10.1007/s00066-016-0987-7.
Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19:759–73. https://doi.org/10.1038/s41579-021-00582-z.
Gulia S, Sengar M, Dangi U, Menon H, Biswas SK, Kelkar RS, et al. Prevalence and patterns of cytomegalovirus (CMV) reactivation in adult acute lymphoblastic leukemia patients on chemotherapy: single center experience. Blood. 2011;118:2583. https://doi.org/10.1182/blood.V118.21.2583.2583.
Hilal T. Fatal cytomegalovirus disease after combination therapy with corticosteroids and rituximab for granulomatosis with polyangiitis. Case Rep Rheumatol. 2015. https://doi.org/10.1155/2015/538137.
Lee BH, Jeon MJ, Yu ES, et al. Prognostic outcomes of cytomegalovirus reactivation after autologous stem cell transplantation. Int J Med Sci. 2023. https://doi.org/10.7150/ijms.79285.
Ozbalak M, Mastanzade M, Gurel E, Kalayoglu BS. Cytomegalovirus reactivation during adult acute lymphoblastic leukemia maintenance: do we underestimate (un)expected guest of pediatric approach? Am J Blood Res. 2021;11:118–22.
Perello R, Vergara A, Monclus E, et al. Cytomegalovirus infection in HIV-infected patients in the era of combination antiretroviral therapy. BMC Infect Dis. 2019;19:1030. https://doi.org/10.1186/s12879-019-4643-6.
Reddy YEA. Cytomegalovirus proctitis in a patient with chronic lymphocytic leukemia on ibrutinib therapy: a case report. Cureus. 2020. https://doi.org/10.7759/cureus.7837.
Torres HA, Dimitrios D, Aguilera EA, et al. Cytomegalovirus infection in patients with lymphoma: an important cause of morbidity and mortality. Clin Lymphoma Myeloma. 2006;6:393–8. https://doi.org/10.3816/CLM.2006.n.016.
Vallejo M, Muñiz P, Kwon M, et al. Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms. Ann Hematol. 2022;101:1567–76. https://doi.org/10.1007/s00277-022-04841-8.
Vancíková Z, Dvorak P. Cytomegalovirus infection in immunocompetent and immunocompromised individuals–a review. Curr Drug Targets Immune Endocr Metabol Disord. 2001;1:179–87.
Zedtwitz-Liebenstein K, Diab-Elschahaw M, Frass M. Human cytomegalovirus infection in nonimmunocompromised patients: a retrospective analysis and review of the literature. Intervirology. 2016;59:159–62. https://doi.org/10.1159/000454772.
Zhang Z, Liu X, Sang L, et al. Cytomegalovirus reactivation in immunocompetent mechanical ventilation patients: a prospective observational study. BMC Infect Dis. 2021;21:1026. https://doi.org/10.1186/s12879-021-06698-0.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.
Consent to participate
Waiver for informed consent granted by the institutional review board.
Ethics approval
This is an observational study. The Institutional Review Board (SKMCH&RC) has confirmed that no ethical approval is required. Exemption approval letter number EX-08-06-22-01.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Mahar, U.R., Jhatial, M.A., Qazi, R. et al. Significance of CMV reactivation in non-allogeneic stem cell transplant patients with cancers: experience of single tertiary care cancer institute. VirusDis. 34, 383–388 (2023). https://doi.org/10.1007/s13337-023-00839-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13337-023-00839-6